Skip to main content
Notice2026-19232

Esther Villanueva Valdes, M.D.; Decision and Order

Primary source

Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.

Published
September 21, 2026

Issuing agencies

Justice DepartmentDrug Enforcement Administration

Full Text

<html>
<head>
<title>Federal Register, Volume 91 Issue 181 (Monday, September 21, 2026)</title>
</head>
<body><pre>
[Federal Register Volume 91, Number 181 (Monday, September 21, 2026)]
[Notices]
[Pages 59798-59800]
From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]
[FR Doc No: 2026-19232]


-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration


Esther Villanueva Valdes, M.D.; Decision and Order

    On February 19, 2025, the Drug Enforcement Administration (DEA or 
Government) issued an Order to Show Cause (OSC) to Esther Villanueva 
Valdes, M.D., of Arecibo, Puerto Rico (Registrant). Request for Final 
Agency Action (RFAA), Exhibit (RFAAX) 1, at 1, 4. The OSC proposed the 
revocation of Registrant's Certification of Registration No. BV4657485, 
alleging that Registrant is ``currently without authority to . . . 
handle controlled substances in the Commonwealth of Puerto Rico, the 
U.S. territory in which [she is] registered with DEA'' and has been 
mandatorily excluded from participation in Medicare, Medicaid, and all 
Federal health care programs pursuant to 42 U.S.C. 1320a-7(a). Id. at 2 
(citing 21 U.S.C. 824(a)(3), (5)).\1\
---------------------------------------------------------------------------

    \1\ According to the OSC and Agency records, Registrant's 
registration expired on May 31, 2025. RFAAX 1, at 2. The fact that a 
registrant allows his or her registration to expire during the 
pendency of an administrative enforcement proceeding does not impact 
the Agency's jurisdiction or prerogative under the Controlled 
Substances Act to adjudicate the OSC to finality. Jeffrey D. Olsen, 
M.D., 84 FR 68474, 68476-79 (2019).
---------------------------------------------------------------------------

    The OSC notified Registrant of her right to file a written request 
for hearing, and that if she failed to file such a request, she would 
be deemed to have waived her right to a hearing and be in default. Id. 
at 3 (citing 21 CFR 1301.43). Here, Registrant did not request a 
hearing, and the Agency finds her to be in default. RFAA, at 3.\2\ ``A 
default, unless excused, shall be deemed to constitute a waiver of the 
registrant's/applicant's right to a hearing and an admission of the 
factual allegations of the [OSC].'' 21 CFR 1301.43(e).
---------------------------------------------------------------------------

    \2\ Based on the Government's submissions in its RFAA dated 
February 12, 2026, the Agency finds that service of the OSC on 
Registrant was adequate. The RFAA's included Declaration from a DEA 
Diversion Investigator (DI) indicates that on February 24, 2025, the 
DI emailed the OSC to Registrant and on that same day Registrant 
acknowledged receipt of the OSC via email. RFAAX 2, at 1; see id., 
Attachment A. Here, the Agency finds that Registrant was 
successfully served the OSC by email.
---------------------------------------------------------------------------

    Further, ``[i]n the event that a registrant . . . is deemed to be 
in default . . . DEA may then file a request for final agency action 
with the Administrator, along with a record to support its request. In 
such circumstances, the Administrator may enter a default final order 
pursuant to [21 CFR] Sec.  1316.67.'' Id. at 1301.43(f)(1). Here, the 
Government has requested final agency action based on Registrant's

[[Page 59799]]

default pursuant to 21 CFR 1301.43(c), (f), and 1301.46. RFAA, at 4; 
see 21 CFR 1316.67.\3\
---------------------------------------------------------------------------

    \3\ The RFAA states that ``the Administrator is authorized to 
render the Agency's final order, without holding a hearing or making 
findings of fact in this matter.'' RFAA, at 3-4 (citing 21 CFR 
1301.43(c), (f), and 1301.46). However, 21 CFR 1316.67 requires that 
the Administrator's final order ``set forth the final rule and 
findings of fact and conclusions of law upon which the rule is 
based.'' See JYA LLC d/b/a Webb's Square Pharmacy, 90 FR 31244, 
31246 n.7 (2025).
---------------------------------------------------------------------------

I. Loss of State Authority

A. Findings of Fact

    The Agency finds that, in light of Registrant's default, the 
factual allegations in the OSC are deemed admitted. 21 CFR 1301.43(e). 
According to the OSC, Registrant's Puerto Rico medical license, issued 
by the Puerto Rico Board of Medical Licensure and Discipline (Board), 
expired on July 4, 2022. RFAAX 1, at 2. Registrant also held a Board 
controlled substance license that expired on August 31, 2023. Id.
    According to Puerto Rico online records, of which the Agency takes 
official notice,\4\ Registrant's medical license is expired and remains 
in such status. Commonwealth of Puerto Rico Department of Health, 
Division of Board of Licensing and Medical Discipline Verification 
Search, <a href="https://orcps.salud.pr.gov/mbps/verificacion">https://orcps.salud.pr.gov/mbps/verificacion</a> (last visited date 
of signature of this Order). Accordingly, the Agency finds that 
Registrant is not licensed to practice medicine in Puerto Rico, the 
jurisdiction in which she is registered with DEA.\5\
---------------------------------------------------------------------------

    \4\ Under the Administrative Procedure Act, an agency ``may take 
official notice of facts at any stage in a proceeding--even in the 
final decision.'' United States Department of Justice, Attorney 
General's Manual on the Administrative Procedure Act 80 (1947) (Wm. 
W. Gaunt & Sons, Inc., Reprint 1979).
    \5\ Pursuant to 5 U.S.C. 556(e), ``[w]hen an agency decision 
rests on official notice of a material fact not appearing in the 
evidence in the record, a party is entitled, on timely request, to 
an opportunity to show the contrary.'' The material fact here is 
that Registrant, as of the date of this Order, is not licensed to 
practice medicine in Puerto Rico. Accordingly, Registrant may 
dispute the Agency's finding by filing a properly supported motion 
for reconsideration of findings of fact within fifteen calendar days 
of the date of this Order. Any such motion and response shall be 
filed and served by email to the other party and to the Office of 
the Administrator, Drug Enforcement Administration, at 
<a href="/cdn-cgi/l/email-protection#87e3e2e6a9e6e3e3e8a9e6f3f3e8f5e9e2fef4c7e3e2e6a9e0e8f1"><span class="__cf_email__" data-cfemail="3a5e5f5b145b5e5e55145b4e4e5548545f43497a5e5f5b145d554c">[email&#160;protected]</span></a>.
---------------------------------------------------------------------------

B. Discussion

    Pursuant to 21 U.S.C. 824(a)(3), the Attorney General is authorized 
to suspend or revoke a registration issued under 21 U.S.C. 823 ``upon a 
finding that the registrant . . . has had his State license or 
registration suspended . . . [or] revoked . . . by competent State 
authority and is no longer authorized by State law to engage in the . . 
. dispensing of controlled substances.'' With respect to a 
practitioner, DEA has also long held that the possession of authority 
to dispense controlled substances under the laws of the state in which 
a practitioner engages in professional practice is a fundamental 
condition for obtaining and maintaining a practitioner's registration. 
See, e.g., James L. Hooper, M.D., 76 FR 71371, 71372 (2011), pet. for 
rev. denied, 481 F. App'x 826 (4th Cir. 2012); Frederick Marsh Blanton, 
M.D., 43 FR 27616, 27617 (1978).\6\
---------------------------------------------------------------------------

    \6\ This rule derives from the text of two provisions of the 
Controlled Substances Act (CSA). First, Congress defined the term 
``practitioner'' to mean ``a physician . . . or other person 
licensed, registered, or otherwise permitted, by . . . the 
jurisdiction in which he practices . . . , to distribute, dispense, 
. . . [or] administer . . . a controlled substance in the course of 
professional practice.'' 21 U.S.C. 802(21). Second, in setting the 
requirements for obtaining a practitioner's registration, Congress 
directed that ``[t]he Attorney General shall register practitioners 
. . . if the applicant is authorized to dispense . . . controlled 
substances under the laws of the State in which he practices.'' 21 
U.S.C. 823(g)(1). Under the CSA, the term ``state'' means ``a State 
of the United States, the District of Columbia, and any 
commonwealth, territory, or possession of the United States,'' 
including Puerto Rico. 21 U.S.C. 802(26). Because Congress has 
clearly mandated that a practitioner possess authority in order to 
be deemed a practitioner under the CSA, DEA has held repeatedly that 
revocation of a practitioner's registration is the appropriate 
sanction whenever he is no longer authorized to dispense controlled 
substances under the laws of the jurisdiction in which he practices. 
See, e.g., James L. Hooper, 76 FR at 71371-72; Sheran Arden Yeates, 
M.D., 71 FR 39130, 39131 (2006); Dominick A. Ricci, M.D., 58 FR 
51104, 51105 (1993); Bobby Watts, M.D., 53 FR 11919, 11920 (1988); 
Frederick Marsh Blanton, 43 FR at 27617.
---------------------------------------------------------------------------

    According to the Puerto Rico Controlled Substances Act, ``[a]ny 
person who manufactures, distributes and dispenses controlled 
substances in the Commonwealth of Puerto Rico . . . shall obtain a 
registration certification annually, issued by the Secretary of Health, 
pursuant to the rules and regulations approved and promulgated by said 
government official.'' P.R. Laws Ann. tit. 24, Sec.  2302(a) (current 
through all acts translated by the Translation Office of the Puerto 
Rico Government through the 2025 Legislative Session). Further, 
``dispense'' means ``the prescribing, administering or delivering of a 
controlled substance to an ultimate user, by prescription or order for 
administering it. It includes the process of the compounding, labeling 
and packaging of a controlled substance for such delivery. The term 
`dispenser' means the practitioner who so delivers a controlled 
substance.'' Id. Sec.  2102(11).
    Here, the undisputed evidence in the record is that Registrant 
lacks authority to dispense controlled substances in Puerto Rico. As 
discussed above, an individual must hold a controlled substance license 
and be licensed to practice medicine to dispense a controlled substance 
in Puerto Rico. Thus, because Registrant lacks authority to handle 
controlled substances in Puerto Rico, Registrant is not eligible to 
maintain a DEA registration in that jurisdiction. Accordingly, the 
Agency will order that Registrant's DEA registration be revoked.
    Registrant's lack of state authority to handle controlled 
substances in Puerto Rico is sufficient by itself to support revoking 
Registrant's DEA registration. Infra n.9. The following mandatory 
exclusion ground provides an additional, independent basis for revoking 
Registrant's DEA registration.

II. Mandatory Exclusion From Federal Health Care Programs

A. Findings of Fact

    Registrant is deemed to admit that on April 7, 2021, in the United 
States District Court for the District of Puerto Rico, Registrant pled 
guilty to one count of healthcare fraud in violation of 18 U.S.C. 1347 
and judgment was entered against her on August 30, 2021.\7\ RFAAX 1, at 
2. As a result of Registrant's guilty plea and criminal conviction, the 
U.S. Department of Health and Human Services, Office of Inspector 
General (HHS/OIG), mandatorily excluded Registrant from participation 
in Medicare, Medicaid, and all Federal health care programs, effective 
March 20, 2022, for a minimum period of 8 years, pursuant to 42 U.S.C. 
1320a-7(a). Id.
---------------------------------------------------------------------------

    \7\ See United States v. Esther Villanueva-Valdes, No. 3:21-cr-
00101-ADC (D.P.R.).
---------------------------------------------------------------------------

B. Discussion

    Pursuant to 21 U.S.C. 824(a)(5), the Attorney General is authorized 
to suspend or revoke a registration issued under section 823 of the CSA 
upon finding that the registrant ``has been excluded (or directed to be 
excluded) from participation in a program pursuant to section 1320a-
7(a) of Title 42.'' The Agency has consistently held that it may also 
deny an application upon finding that an applicant has been excluded 
from a federal health care program. Mark Agresti, M.D., 90 FR 30098, 
30099 (2025); Samirkumar Shah, M.D., 89 FR 71931, 71933 (2024); 
Arvinder Singh, M.D., 81 FR 8247, 8248 n.3 (2016).
    The Agency finds substantial record evidence that Registrant has 
been, and

[[Page 59800]]

remains, mandatorily excluded from federal health care programs 
pursuant to 42 U.S.C. 1320a-7(a).\8\ Accordingly, the Agency finds that 
substantial record evidence establishes the Government's prima facie 
case for revocation of Registrant's registration under 21 U.S.C. 
824(a)(5).
---------------------------------------------------------------------------

    \8\ The underlying conviction forming the basis for mandatory 
exclusion from participation in federal health care programs need 
not involve controlled substances to provide the grounds for 
revocation or denial pursuant to Section 824(a)(5). Jeffrey Stein, 
M.D., 84 FR 46968, 46971-72 (2019); Narciso Reyes, M.D., 83 FR 
61678, 61681 (2018); KK Pharmacy, 64 FR 49507, 49510 (1999) 
(collecting cases).
---------------------------------------------------------------------------

III. Sanction

    Where, as here, the Government has met its prima facie burden of 
showing that Registrant's registration should be revoked, the burden 
shifts to Registrant to show why she can be entrusted with a 
registration. Morall v. Drug Enf't Admin., 412 F.3d. 165, 174 (D.C. 
Cir. 2005); Jones Total Health Care Pharmacy, LLC v. Drug Enf't Admin., 
881 F.3d 823, 830 (11th Cir. 2018); Garrett Howard Smith, M.D., 83 FR 
18882 (2018). The issue of trust is necessarily a fact-dependent 
determination based on the circumstances presented by the individual 
practitioner. Jeffrey Stein, M.D., 84 FR 46968, 46972 (2019); see Jones 
Total Health Care Pharmacy, 881 F.3d at 833. Moreover, as past 
performance is the best predictor of future performance, DEA 
Administrators have required that a registrant who has committed acts 
inconsistent with the public interest must accept responsibility for 
those acts and demonstrate that the registrant will not engage in 
future misconduct. Jones Total Health Care Pharmacy, 881 F.3d at 833; 
ALRA Labs, Inc. v. Drug Enf't Admin., 54 F.3d 450, 452 (7th Cir. 1995). 
Historically, the Agency has considered acceptance of responsibility, 
egregiousness, and deterrence when making this assessment. See Michael 
Bouknight, 90 FR 31247, 31250 (2025); Sasha Melissa Ikramelahai, 90 FR 
32017, 32020-21 (2025); Frank Joseph Stirlacci, M.D., 85 FR 45229, 
45239-40 (2020).
    The Agency requires a registrant's unequivocal acceptance of 
responsibility. Janet S. Pettyjohn, D.O., 89 FR 82639, 82641 (2024); 
Mohammed Asgar, M.D., 83 FR 29569, 29573 (2018); see Jones Total Health 
Care Pharmacy, 881 F.3d at 830-31. In addition, a registrant's candor 
during the investigation and hearing, if one is requested, is an 
important factor in determining acceptance of responsibility and the 
appropriate sanction. See Jones Total Health Care Pharmacy, 881 F.3d at 
830-31; Hoxie v. Drug Enf't Admin., 419 F.3d 477, 483-84 (6th Cir. 
2005). Further, the Agency has found that the egregiousness and extent 
of the misconduct are significant factors in determining the 
appropriate sanction. Jones Total Health Care Pharmacy, 881 F.3d at 833 
n.4, 834. The Agency also considers the need to deter similar acts by a 
registrant and by the community of registrants. Jeffrey Stein, M.D., 84 
FR at 46972-73.
    Here, Registrant did not timely request a hearing or answer the 
allegations in the OSC and was deemed to be in default. To date, 
Registrant has not filed a motion with the Office of the Administrator 
to excuse the default. 21 CFR 1301.43(c)(1). Registrant has thus failed 
to properly answer the allegations contained in the OSC and has not 
otherwise availed herself of the opportunity to refute the Government's 
case. As such, Registrant has not accepted responsibility for the 
proven violations, has made no representations regarding her future 
compliance with the CSA, and has not demonstrated that she can be 
trusted with registration.
    Accordingly, the Agency will order the revocation of Registrant's 
registration.\9\
---------------------------------------------------------------------------

    \9\ In this matter there are two separate and distinct grounds 
by which the Government proposed revocation, Registrant's lack of 
state authority and her mandatory exclusion; each ground, standing 
alone, supports the Agency's decision to revoke.
---------------------------------------------------------------------------

Order

    Pursuant to 28 CFR 0.100(b) and the authority vested in me by 21 
U.S.C. 824(a), I hereby revoke DEA Certificate of Registration No. 
BV4657485, issued to Esther Villanueva Valdes, M.D. Further, pursuant 
to 28 CFR 0.100(b) and the authority vested in me by 21 U.S.C. 
823(g)(1), I hereby deny any pending applications of Esther Villanueva 
Valdes, M.D., to renew or modify this registration, as well as any 
other pending application of Esther Villanueva Valdes, M.D., for 
additional registration in Puerto Rico. This Order is effective October 
21, 2026.

Signing Authority

    This document of the Drug Enforcement Administration was signed on 
September 11, 2026, by DEA Administrator Terrance C. Cole. That 
document with the original signature and date is maintained by DEA. For 
administrative purposes only, and in compliance with requirements of 
the Office of the Federal Register, the undersigned DEA Federal 
Register Liaison Officer has been authorized to sign and submit the 
document in electronic format for publication, as an official document 
of DEA. This administrative process in no way alters the legal effect 
of this document upon publication in the Federal Register.

Heather Achbach,
Federal Register Liaison Officer, Drug Enforcement Administration.
[FR Doc. 2026-19232 Filed 9-18-26; 8:45 am]
BILLING CODE 4410-09-P


</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>
Indexed from Federal Register on September 21, 2026.

This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.